We are live on ! Find out more
KRTX

Karuna Therapeutics, Inc. Common Stock

Delisted

KRTX was delisted on the 15th of March, 2024.

143 hedge funds and large institutions have $2.19B invested in Karuna Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 48 increasing their positions, 46 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more call options, than puts

Call options by funds: $17.2M | Put options by funds: $7.32M

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

69% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 16

40% more capital invested

Capital invested by funds: $1.56B → $2.19B (+$629M)

8% more funds holding

Funds holding: 132143 (+11)

4% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 46

Holders
143
Holders Change
+11
Holders Change %
+8.33%
% of All Funds
2.53%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
27
Increased
48
Reduced
46
Closed
16
Calls
$17.2M
Puts
$7.32M
Net Calls
+$9.89M
Net Calls Change
+$12.8M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$474M +$62.2M +671,720 +17%
SI
2
Sofinnova Investments
California
$198M
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$145M +$4.55M +49,073 +4%
BlackRock
4
BlackRock
New York
$140M +$7.98M +86,154 +7%
Vanguard Group
5
Vanguard Group
Pennsylvania
$124M +$2.39M +25,847 +2%
PBPIA
6
Pivotal bioVenture Partners Investment Advisor
California
$110M +$100M +1,083,344 New
EAM
7
Eventide Asset Management
Massachusetts
$91.5M
State Street
8
State Street
Massachusetts
$78.7M -$2.32M -25,057 -3%
FCM
9
Farallon Capital Management
California
$71.1M
PAMU
10
Pictet Asset Management (UK)
United Kingdom
$56.4M -$10M -107,890 -16%
Federated Hermes
11
Federated Hermes
Pennsylvania
$53.4M +$17.2M +185,872 +55%
Sands Capital Management
12
Sands Capital Management
Virginia
$43.6M
Capital International Investors
13
Capital International Investors
California
$38M -$8.46M -91,300 -20%
Viking Global Investors
14
Viking Global Investors
Connecticut
$34.4M -$30.2M -325,690 -49%
Lord, Abbett & Co
15
Lord, Abbett & Co
New Jersey
$28M +$616K +6,648 +2%
EAM
16
Eagle Asset Management
Florida
$27.2M -$2.47M -26,651 -9%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$26M +$657K +7,091 +3%
UBS AM
18
UBS AM
Illinois
$25.2M +$2.19M +23,658 +11%
RSCM
19
Rock Springs Capital Management
Maryland
$24.8M -$14.5K -156 -0.1%
CII
20
Capital International Inc
California
$23.3M -$258K -2,789 -1%
Ensign Peak Advisors
21
Ensign Peak Advisors
Utah
$20.2M +$2.5M +26,996 +16%
CTA
22
Carillon Tower Advisers
Florida
$18.7M -$1.05M -11,369 -6%
Northern Trust
23
Northern Trust
Illinois
$18.5M -$330K -3,557 -2%
Norges Bank
24
Norges Bank
Norway
$18.2M +$298K +3,213 +2%
Goldman Sachs
25
Goldman Sachs
New York
$14.7M +$4.87M +52,591 +57%

KRTX Hedge Fund Activity: Q4 2020 in Review

143 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q4 2020, worth a combined $2.19B — up 40% from $1.56B a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new KRTX positions and 16 closed out — a net gain of 11 holders — while 48 added to existing stakes and 46 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $62.2M. The largest seller was Fidelity International, cutting an estimated $62.2M.

  • 143 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q4 2020, up from 132 in Q3 2020.
  • Funds reported $2.19B of Karuna Therapeutics, Inc. Common Stock stock for Q4 2020, up 40% quarter-over-quarter.
  • 27 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q4 2020 and 16 closed out, a net change of +11 holders.
  • The largest Karuna Therapeutics, Inc. Common Stock buyer in Q4 2020 was Fidelity Investments, an estimated $62.2M added.
  • The largest Karuna Therapeutics, Inc. Common Stock seller in Q4 2020 was Fidelity International, an estimated $62.2M sold.

Based on aggregated 13F filings for Q4 2020.